Population health management
Integrated NHS finances: what do they mean for High Cost Drugs?
Oli Hudson and Steve How, of Wilmington Healthcare, explore NHS England’s new system-level funding and its impact on prescribing for High Cost Drugs
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond
Putting disease prevention on a par with cure
Steve How and Paul Midgley, of the Wilmington Healthcare Consulting Team, explore how the NHS is taking an increasingly holistic approach to care
What does the new NHS plan mean for pharma?
Steve How and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of the NHS Long-term Plan
How can the NHS deliver integrated care?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, explain the changes needed to help the NHS provide a more holistic, joined up experience for patients
How the focus on patient outcomes has allowed FMCG to enter into healthcare market
Associate Consultant Mette Drabæk talks about how the increase in ability to measure real-world patient outcomes has strengthened the position of the payer when negotiating reimbursement contracts with pharma companies.